Due to the COVID-19 pandemic, the ACP office is now closed as our staff work remotely. Click here to see how this impacts our programs and operations.

Buprenorphine/naloxone products move to Type 2 TPP Alberta status

Effective July 15, 2019, buprenorphine/naloxone products will move from Type 1 to Type 2 TPP status in Alberta. As a result, these products will no longer require use of a secure TPP prescription form. Buprenorphine/naloxone products will continue to be monitored through TPP Alberta as a Type 2 drug.

Single entity buprenorphine (e.g., Butrans patches) and all buprenorphine products for veterinary use will remain a Type 1 TPP drug which means a secure TPP form is still required.

For more information on TPP Alberta, visit: http://www.cpsa.ca/tpp/